Results 251 to 260 of about 20,614 (289)

Retrospective analysis of influences of sacubitril/valsartan in patients with diabetes with poorly controlled blood pressure in Japan. [PDF]

open access: yesJ Diabetes Investig
Ito S   +19 more
europepmc   +1 more source

Sacubitril/Valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: an opportunity to prevent progressive disease

Cardiovascular Diabetology
Diabetic cardiomyopathy (DbCM) is recognised as a key mediator and determinant of heart failure (HF), particularly HF with preserved ejection fraction (HFpEF). Improved understanding of mechanisms underlying transition from early-stage DbCM to HFpEF will
Narainrit Karuna   +6 more
semanticscholar   +1 more source

Tolerability and beneficial effects of sacubitril/valsartan on systemic right ventricular failure

Heart, 2023
Objective Patients with a systemic right ventricle (sRV) in the context of transposition of the great arteries (TGA) after atrial switch or congenitally corrected TGA (ccTGA) are prone to sRV dysfunction.
M. Nederend   +10 more
semanticscholar   +1 more source

Primary cardioprotective effect of sacubitril/valsartan in breast cancer patients receiving adjuvant therapy

European Journal of Heart Failure
Cancer therapy‐related cardiac dysfunction (CTRCD) can adversely affect clinical outcomes in patients with cancer. The cardioprotective effects of sacubitril/valsartan in preventing CTRCD remain underexplored.
Yu-Ling Hsu   +13 more
semanticscholar   +1 more source

Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial.

Journal of the American Medical Association (JAMA)
Importance The efficacy and safety of guideline-recommended treatments for heart failure (HF) are uncertain in patients with Chagas disease. Objective To evaluate the efficacy and safety of the angiotensin receptor-neprilysin inhibitor sacubitril ...
Renato D. Lopes   +176 more
semanticscholar   +1 more source

Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial

Circulation
BACKGROUND: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is an established treatment for heart failure (HF) with reduced left ventricular ejection fraction.
Robert Shaddy   +39 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy